Vitamin K for improved anticoagulation control in patients receiving warfarin

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 5, 2014, Pages

  Mahtani, Kamal R ^a   Heneghan, Carl J ^a   Nunan, David ^a   Roberts, Nia W ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT;

ANTICOAGULATION; COST EFFECTIVENESS ANALYSIS; DRUG RESPONSE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; VITAMIN SUPPLEMENTATION; BLOOD CLOTTING; DRUG EFFECTS; META ANALYSIS; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION; HUMANS; INTERNATIONAL NORMALIZED RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAMIN K; WARFARIN;

EID: 84942773100     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009917.pub2     Document Type: Review

References (47)

1. Dalloul G, Ghanbari H, Hasan R, Feldman D, Hourani R, Shkri D, et al.The effect of vitamin K supplementation on anticoagulation stability in a community based cardiology practice. Conference: 31st Annual Scientific Sessions of the Heart Rhythm Society, Heart Rhythm; 2010 May 12-15; Denver (CO). 2010; Vol. 7 (5 Suppl 1):S88.
2. Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2007;109(6):2419-23. [PUBMED: 17110451].
3. de Assis MC, Rabelo ER, Avila CW, Polanczyk CA, Rohde LE. Improved oral anticoagulation after a dietary vitamin k-guided strategy: a randomized controlled trial. Circulation 2009;120(12):1115-22. [PUBMED: 19738137].
4. Ford SK, Misita CP, Shilliday BB, Malone RM, Moore CG, Moll S. Prospective study of supplemental vitamin K therapy in patients on oral anticoagulants with unstable international normalized ratios. Journal of Thrombosis and Thrombolysis 2007;24(1):23-7. [PUBMED: 17323135].
5. Ford SK, Moll S. Vitamin K supplementation to decrease variability of international normalized ratio in patients on vitamin K antagonists: a literature review. Current Opinion in Hematology 2008;15(5):504-8. [PUBMED: 18695375].
6. Gebuis EPA, Rosendaal FR, Van Meegen E, Van Der Meer FJM. The effect of polymorphisms of CYP2C9 and VKORC1 on stability of the INR when supplemented with vitamin K1. 23rd Congress of the International Society on Thrombosis and Haemostasis 57th Annual SSC Meeting; 2011 July 23-28; Kyoto, Japan. 2011.
7. [No authors listed]. Does adding vitamin K to warfarin improve anticoagulation control?. Journal of Family Practice 2008;57(4):221. [PUBMED: 18399017].
8. Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS Jr. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. Journal of Clinical Pharmacology 2001;41(7):715-22. [PUBMED: 11452703].
9. Marongiu F, Sorano GG, Conti M, Mameli G, Biondi G, Licheri D, et al.Known vitamin K intake and management of poorly controlled oral anticoagulant therapy. Lancet 1992;340(8818):545-6. [PUBMED: 1354291].
10. NTR314. Low dose vitamin K to improve therapeutic quality control of oral anticoagulant treatment: a randomized double-blind placebo controlled trial. http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=314 2005.
11. Patriquin C, Crowther M. Treatment of warfarin-associated coagulopathy with vitamin K. Expert Review of Hematology 2011;4(6):657-67. [PUBMED: 22077529].
12. Pedersen FM, Hamberg O, Hess K, Ovesen L. The effect of dietary vitamin K on warfarin-induced anticoagulation. Journal of Internal Medicine 1991;229(6):517-20. [PUBMED: 2045759].
13. Pengo V, Banzato A, Garelli E, Zasso A, Biasiolo A. Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. Blood Coagulation & Fibrinolysis 1993;4(5):739-41. [PUBMED: 8292723].
14. Rombouts EK, Rosendaal FR, Van Der Meer FJ. Daily vitamin K supplementation improves anticoagulant stability. Journal of Thrombosis and Haemostasis 2007; Vol. 5, issue 10:2043-8. [PUBMED: 17666020].
15. Shopnick R, Passamonte J, Cantrell W. Excessive anticoagulation in warfarin treated patients managed with phytonadione administration vs observation. Blood 1998;10 Suppl 1 (Pt 1):361a, abstract 1486.
16. Sorano GG, Biondi G, Conti M, Mameli G, Licheri D, Marongiu F. Controlled vitamin K content diet for improving the management of poorly controlled anticoagulated patients: a clinical practice proposal. Haemostasis 1993;23(2):77-82. [PUBMED: 8365689].
17. Udall JA. Stabilization of anticoagulant therapy by simultaneous coumarin and vitamin K administration. Angiology 1968;19(2):95-102. [PUBMED: 4868165].
18. Zuchinali P, Souza GC, de Assis MC, Rabelo ER, Rohde LE. Dietary vitamin K intake and stability of anticoagulation with coumarins: evidence derived from a clinical trial. Nutricíon Hospitalaria 2012;27(6):1987-92. [PUBMED: 23588449].
19. NCT00794755. A phase III pilot RCT (randomized, controlled trial) to assess the effectiveness of low dose vitamin K1 (200 micrograms per day) on improving anticoagulation control in unstable patients on warfarin. http://clinicaltrials.gov/show/NCT00794755.
20. NCT00990158. A multicentre study of low dose oral vitamin K for INR control in patients receiving warfarin. http://clinicaltrials.gov/ct2/show/NCT00990158.
21. Azar AJ, Deckers JW, Rosendaal FR, van Bergen PF, van der Meer FJ, Jonker JJ, et al.Assessment of therapeutic quality control in a long-term anticoagulant trial in post-myocardial infarction patients. Thrombosis and Haemostasis 1994;72(3):347-51. [PUBMED: 7855782].
22. Baglin TP, Keeling DM, Watson HG, British Committee for Standards in Haematology. Guidelines on oral anticoagulation (warfarin): third edition--2005 update. British Journal of Haematology 2006;132(3):277-85. [PUBMED: 16409292].
23. British National Formulary. www.bnf.org 2013.
24. Booth SL, Centurelli MA. Vitamin K: a practical guide to the dietary management of patients on warfarin. Nutrition Reviews 1999;57(9 Pt 1):288-96. [PUBMED: 10568341].
25. Choonara IA, Malia RG, Haynes BP, Hay CR, Cholerton S, Breckenridge AM, et al.The relationship between inhibition of vitamin K1 2, 3-epoxide reductase and reduction of clotting factor activity with warfarin. British Journal of Clinical Pharmacology 1988;25(1):1-7. [PUBMED: 3370190].
26. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian atrial fibrillation anticoagulation (CAFA) study. Journal of the American College of Cardiology 1991;18(2):349-55. [PUBMED: 1856403].
27. Dalloul G. Personal communication via email confirming that no further publications were made after this abstract. 24 May 2013.
28. No authors listed. Self-monitoring for patients on warfarin?. Drug and Therapeutics Bulletin 2009;47:98-101. [DOI: 10.1136/dtb.2009.08.0036].
29. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al.Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators. The New England Journal of Medicine 1992;327(20):1406-12. [PUBMED: 1406859].
30. Franco V, Polanczyk CA, Clausell N, Rohde LE. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. The American Journal of Medicine 2004;116(10):651-6. [PUBMED: 15121490].
31. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, et al.Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. JAMA: the Journal of the American Medical Association 2003;290(20):2685-92. [PUBMED: 14645310].
32. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006;367(9508):404-11. [PUBMED: 16458764].
33. Heneghan C, Tyndel S, Bankhead C, Wan Y, Keeling D, Perera R, et al.Optimal loading dose for the initiation of warfarin: a systematic review. BMC Cardiovascular Disorders 2010;10:18. [PUBMED: 20403189].
34. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
35. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al.Systematic overview of warfarin and its drug and food interactions. Archives of Internal Medicine 2005;165(10):1095-106. [PUBMED: 15911722].
36. Lefebvre C, Manheimer E, Glenville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook forSystematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
37. McIlroy DR, Myles PS, Phillips LE, Smith JA. Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic review and meta-analysis. British Journal of Anaesthesia 2009;102(2):168-78. [PUBMED: 19151047].
38. Medicines and Healthcare products Regulatory Agency (MHRA). MHRA Public Assessment Report. Warfarin: changes to product safety information. http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con065506.pdf 2009:Website accessed 12th February 2014.
39. National Institute for Health and Clinical Excellence (NICE). Assumptions used in estimating a population benchmark. http://www.slcsn.nhs.uk/af/files/treatment/anticoagulation/af-nice-anticoag-guidelines.pdf (accessed 13 May 2014).
40. National Institute for Health and Clinical Excellence (NICE). Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation.. http://guidance.nice.org.uk/TA249 March 2012, issue Website accessed 12th February 2014.
41. Rohde LE, de Assis MC, Rabelo ER. Dietary vitamin K intake and anticoagulation in elderly patients. Current Opinion in Clinical Nutrition and Metabolic Care 2007;10(1):1-5. [PUBMED: 17143047].
42. Rosenman M, Simon T, Teal E, McGuire P, Jackson J, Tierney W. Atrial fibrillation and warfarin: time in therapeutic range - an electronic medical record system study of real-world practice. Circulation 2009;120:S521.
43. Sconce E, Khan T, Mason J, Noble F, Wynne H, Kamali F. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thrombosis and Haemostasis 2005;93(5):872-5. [PUBMED: 15886802].
44. Sorensen SV, Dewilde S, Singer DE, Goldhaber SZ, Monz BU, Plumb JM. Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. American Heart Journal 2009;157(6):1064-73. [PUBMED: 19464418].
45. van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, et al.Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke; a Journal of Cerebral Circulation 2009;40(4):1410-6. [PUBMED: 19182090].
46. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, et al.Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circulation. Cardiovascular Quality and Outcomes 2008;1(2):84-91. [PUBMED: 20031794].
47. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Archives of Internal Medicine 2007;167(13):1414-9. [PUBMED: 17620536].